MindMed Engages in Productive Pre-Submission Meeting with FDA for Development of the MindMed Session Monitoring System

Mind Medicine, a leading biotech company developing psychedelic-inspired therapies recently met with the United States Food and Drug Administration Center for Devices and Radiological Health with consultation from the Center for Drug Evaluation and Research concerning several key points for ongoing development of the MindMed Session Monitoring System in a device pre-submission meeting that took place on October 25, 2021.